Bausch Health (BHC) and its Salix Pharmaceuticals unit acknowledged Friday the inclusion of Xifaxan 550 milligram tablets in the second round of price negotiations under the Inflation Reduction Act.
Bausch Health and Salix said they look forward to the discussions with the US Department of Health and Human Services' Centers for Medicare and Medicaid Services, or CMS.
In a separate statement, CMS said negotiations will be conducted this year and any negotiated prices will take effect in 2027.
Drug companies with a selected drug for price negotiations have until Feb. 28 to decide on their participation in the talks, according to the statement.
Price: 7.63, Change: -0.02, Percent Change: -0.26
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。